Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Fengcai Zhu, Lihua Hou et al.|Emerging Microbes & Infections|2022Cited by 30
Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previouslyLairun Jin, Fengcai Zhu, Yin Chen et al.|medRxiv|2022Cited by 10
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trialPengfei Jin, Jingxin Li, Yawen Zhu et al.|Expert Review of Vaccines|2024Cited by 0